Liminatus Pharma, Inc. (LIMN)

NASDAQ: LIMN · Real-Time Price · USD

2.780

-0.560 (-16.77%)

Aug 21, 2025, 4:00 PM - Market closed

Liminatus Pharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Selling, General & Admin	0.65	0.65	1.06	0.86
Research & Development	2.69	2.69	3.76	1.85
Operating Expenses	3.33	3.33	4.82	2.71
Operating Income	-3.33	-3.33	-4.82	-2.71
Interest Expense	-0.34	-0.34	-0.18	-0.22
Interest & Investment Income	0.12	0.12	0.01	-
Pretax Income	-3.55	-3.55	-4.98	-2.93
Net Income	-3.55	-3.55	-4.98	-2.93
Net Income to Common	-3.55	-3.55	-4.98	-2.93
Shares Outstanding (Basic)	26	112	102	36
Shares Outstanding (Diluted)	26	112	102	36
Shares Change (YoY)	-74.62%	9.49%	188.25%	-
EPS (Basic)	-0.14	-0.03	-0.05	-0.08
EPS (Diluted)	-0.14	-0.03	-0.05	-0.08
EBIT	-3.33	-3.33	-4.82	-2.71

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q